Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Citations for PubMed (Select 23696101)

1.

Completeness of prescription information in US commercial claims databases.

Lauffenburger JC, Balasubramanian A, Farley JF, Critchlow CW, O'Malley CD, Roth MT, Pate V, Brookhart MA.

Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):899-906. doi: 10.1002/pds.3458. Epub 2013 May 21.

2.

Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.

Kwong WJ, Kamat S, Fang C.

Ann Pharmacother. 2012 Dec;46(12):1609-16. doi: 10.1345/aph.1Q472. Epub 2012 Nov 13.

PMID:
23150608
3.

Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims.

Qualls LG, Greiner MA, Eapen ZJ, Fonarow GC, Mills RM, Klaskala W, Hernandez AF, Curtis LH.

Clin Cardiol. 2013 Dec;36(12):757-65. doi: 10.1002/clc.22206. Epub 2013 Oct 1.

PMID:
24114926
4.

Prevalence and predictors of utilization of community pharmacy generic drug discount programs.

Gatwood J, Tungol A, Truong C, Kucukarslan SN, Erickson SR.

J Manag Care Pharm. 2011 Jul-Aug;17(6):449-55.

5.

Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis.

Ghate SR, Biskupiak JE, Ye X, Hagan M, Kwong WJ, Fox ES, Brixner DI.

Ann Pharmacother. 2011 Jun;45(6):701-12. doi: 10.1345/aph.1P593. Epub 2011 Jun 10.

PMID:
21666081
6.

Completeness of retail pharmacy claims data: implications for pharmacoepidemiologic studies and pharmacy practice in elderly patients.

Polinski JM, Schneeweiss S, Levin R, Shrank WH.

Clin Ther. 2009 Sep;31(9):2048-59. doi: 10.1016/j.clinthera.2009.09.009.

7.

Risk of hemorrhage and treatment costs associated with warfarin drug interactions in patients with atrial fibrillation.

Suh DC, Nelson WW, Choi JC, Choi I.

Clin Ther. 2012 Jul;34(7):1569-82. doi: 10.1016/j.clinthera.2012.05.008. Epub 2012 Jun 19.

PMID:
22717419
8.

Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.

Agarwal S, Bennett D, Smith DJ.

Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.

PMID:
20104933
9.

Health care burden of dyspepsia among nonvalvular atrial fibrillation patients.

Kim MH, Bell KF, Makenbaeva D, Wiederkehr D, Lin J, Graham J.

J Manag Care Spec Pharm. 2014 Apr;20(4):391-9.

10.

Substitution of generic warfarin for Coumadin in an HMO setting.

Milligan PE, Banet GA, Waterman AD, Gatchel SK, Gage BF.

Ann Pharmacother. 2002 May;36(5):764-8.

PMID:
11978149
11.

Validating a method that deals with missing drug information in the Saskatchewan Drug Plan database.

Tamim HM, Tagalakis V.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):140-6. doi: 10.1002/pds.1692.

PMID:
19090502
12.

Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching.

Halkin H, Shapiro J, Kurnik D, Loebstein R, Shalev V, Kokia E.

Clin Pharmacol Ther. 2003 Sep;74(3):215-21.

PMID:
12966365
13.

Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database.

Liou WS, Hsieh SC, Chang WY, Wu GH, Huang HS, Lee C.

Pharmacoepidemiol Drug Saf. 2013 Jul;22(7):752-9. doi: 10.1002/pds.3445. Epub 2013 Apr 29.

PMID:
23625864
14.

Evidence of sample use among new users of statins: implications for pharmacoepidemiology.

Li X, Stürmer T, Brookhart MA.

Med Care. 2014 Sep;52(9):773-80. doi: 10.1097/MLR.0000000000000174.

PMID:
24984210
15.

Pharmacoepidemiologic study of warfarin prescription in a Brazilian tertiary hospital.

Guidoni CM, Obreli-Neto PR, Pereira LR.

J Thromb Thrombolysis. 2014 May;37(4):542-8. doi: 10.1007/s11239-013-1030-9.

PMID:
24264960
17.

Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.

Amin A, Stokes M, Wu N, Gatt E, Makenbaeva D, Wiederkehr D, Boulanger L.

J Med Econ. 2013 Oct;16(10):1193-202. doi: 10.3111/13696998.2013.828064. Epub 2013 Aug 7.

PMID:
23883416
18.

Validity and representativeness of the "Disease Analyzer" patient database for use in pharmacoepidemiological and pharmacoeconomic studies.

Becher H, Kostev K, Schröder-Bernhardi D.

Int J Clin Pharmacol Ther. 2009 Oct;47(10):617-26.

PMID:
19825325
19.

Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.

Hess PL, Greiner MA, Fonarow GC, Klaskala W, Mills RM, Setoguchi S, Al-Khatib SM, Hernandez AF, Curtis LH.

Clin Cardiol. 2012 Nov;35(11):649-57. doi: 10.1002/clc.22064. Epub 2012 Oct 15.

20.

Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.

Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, Halperin JL, Becker RC, Breithardt G, Hankey GJ, Hacke W, Nessel CC, Patel MR, Califf RM, Fox KA; ROCKET AF Investigators.

J Am Heart Assoc. 2013 Feb 19;2(1):e000067. doi: 10.1161/JAHA.112.000067.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk